Skip to main content
Scientific

The CiMUS spin-off from USC, Smart Vitamins, raises €2.1 million to fund the first clinical trial of its flu prevention therapy.

  • With the support of high-value strategic investors from the pharmaceutical, biomedical, and financial sectors.
  • It will begin in early 2026 in the United Kingdom.

The CiMUS spin-off from USC, Smart Vitamins, co-founded and scientifically led by María José Alonso, has raised €2.1 millions to fund the first clinical trial of its flu therapy, SV B – I. The operation has garnered support from high-value strategic investors, including executives from the pharmaceutical, biomedical, and financial sectors.

Among the investors are Vicente Durán, president of the Medpoint group; Antonio Parente, president of GP Pharm and BCN Peptides; Roberto Conde, founder of Nutrición Médica Cantabria Labs; Santiago Domínguez, partner at Sémola Ventures and president of SCiY (Bruker Biospin division); Mauricio Peralta, general director of the Medpoint group; José Luis del Río, CEO of Arcano; and Roberto Pomares, managing partner at Addleshaw Goddard Spain.

 

Prevention in 100% of cases

This therapy has been developed using the Smart Delivery of Nutrients Technology (SDN) platform, created by María José Alonso's laboratory. Preclinical trials conducted on rodents have successfully prevented the development of the flu in 100% of cases after being infected with the Influenza virus.

"This highly versatile technological platform, protected by a family of internationally-reaching patents, has applications in the pharmaceutical, nutraceutical, and cosmetic markets. It has allowed us to create the SV B – I therapy, which has shown very significant results in efficacy trials conducted on rodents, and we hope it will also achieve the same results in the clinical efficacy trial with humans, which we will begin in early 2026 in the United Kingdom," explain those at Smart Vitamins.